Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D&#8482; trial.

Groop, Per-Henrik; Cooper, Mark E; Perkovic, Vlado; Sharma, Kumar; Schernthaner, Guntram; Haneda, Masakazu; Hocher, Berthold; Gordat, Maud; Cescutti, Jessica; Woerle, Hans-Juergen; von Eynatten, Maximilian

Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial.

Groop, Per-Henrik; Cooper, Mark E; Perkovic, Vlado; Sharma, Kumar; Schernthaner, Guntram; Haneda, Masakazu; Hocher, Berthold; Gordat, Maud; Cescutti, Jessica; Woerle, Hans-Juergen; von Eynatten, Maximilian.

Afiliação

Groop PH; Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, Finland Division of Nephrology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland Baker IDI Heart & Diabetes Institute, Melbourne, VIC, Australia per-henrik.groop@helsinki.f
Cooper ME; Baker IDI Heart & Diabetes Institute, Melbourne, VIC, Australia.
Perkovic V; The George Institute for Global Health, University of Sydney, Sydney, NSW, Australia.
Sharma K; Research Service and Division of Nephrology-Hypertension, Veterans Affairs San Diego Healthcare System, Veterans Medical Research Foundation, San Diego, CA, USA Center for Renal Translational Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
Schernthaner G; Department of Internal Medicine, Rudolfstiftung Hospital, Vienna, Austria.
Haneda M; Division of Metabolism and Biosystemic Science, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan.
Hocher B; Institute of Nutritional Science, University of Potsdam, Potsdam, Germany.
Gordat M; Boehringer Ingelheim, Reims, France.
Cescutti J; Boehringer Ingelheim, Reims, France.
Woerle HJ; Boehringer Ingelheim, Ingelheim, Germany.
von Eynatten M; Boehringer Ingelheim, Ingelheim, Germany.

Diab Vasc Dis Res ; 12(6): 455-62, 2015 Nov.

Article em En | MEDLINE | ID: mdl-26224765

Assuntos

Albuminúria/dietoterapia; Glicemia/efeitos dos fármacos; Diabetes Mellitus Tipo 2/tratamento farmacológico; Inibidores da Dipeptidil Peptidase IV/uso terapêutico; Hiperglicemia/tratamento farmacológico; Hipoglicemiantes/uso terapêutico; Nefropatias/complicações; Nefropatias/etiologia; Linagliptina/uso terapêutico; Adolescente; Adulto; Idoso; Idoso de 80 Anos ou mais; Albuminúria/sangue; Diabetes Mellitus Tipo 2/complicações; Método Duplo-Cego; Feminino; Humanos; Masculino; Pessoa de Meia-Idade; Resultado do Tratamento; Adulto Jovem

Palavras-chave

Dipeptidyl peptidase-4 inhibition; albuminuria; chronic kidney disease; glycaemic control; linagliptin; type 2 diabetes

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Glicemia / Diabetes Mellitus Tipo 2 / Albuminúria / Inibidores da Dipeptidil Peptidase IV / Linagliptina / Hiperglicemia / Hipoglicemiantes / Nefropatias Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Diab Vasc Dis Res Assunto da revista: ANGIOLOGIA / ENDOCRINOLOGIA Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Austrália

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google